Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation.

Moes DJ, Swen JJ, den Hartigh J, van der Straaten T, van der Heide JJ, Sanders JS, Bemelman FJ, de Fijter JW, Guchelaar HJ.

CPT Pharmacometrics Syst Pharmacol. 2014 Feb 12;3:e100. doi: 10.1038/psp.2013.78.

2.

CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.

Li DY, Teng RC, Zhu HJ, Fang Y.

Int J Clin Pharmacol Ther. 2013 Jun;51(6):466-74. doi: 10.5414/CP201836.

PMID:
23557867
3.

CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients.

Picard N, Rouguieg-Malki K, Kamar N, Rostaing L, Marquet P.

Transplantation. 2011 Mar 27;91(6):652-6. doi: 10.1097/TP.0b013e31820ae4ac.

4.

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

Staatz CE, Goodman LK, Tett SE.

Clin Pharmacokinet. 2010 Mar;49(3):141-75. doi: 10.2165/11317350-000000000-00000. Review.

PMID:
20170205
5.

Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients.

Elens L, Hesselink DA, Bouamar R, Budde K, de Fijter JW, De Meyer M, Mourad M, Kuypers DR, Haufroid V, van Gelder T, van Schaik RH.

Ther Drug Monit. 2014 Feb;36(1):71-9. doi: 10.1097/FTD.0b013e31829da6dd.

PMID:
24061445
6.

Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.

Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T.

Clin Pharmacol Ther. 2003 Sep;74(3):245-54.

PMID:
12966368
7.

CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.

Deininger KM, Vu A, Page RL 2nd, Ambardekar AV, Lindenfeld J, Aquilante CL.

Clin Transplant. 2016 Sep;30(9):1074-81. doi: 10.1111/ctr.12790.

PMID:
27314545
8.

Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.

Elens L, Capron A, van Schaik RH, De Meyer M, De Pauw L, Eddour DC, Latinne D, Wallemacq P, Mourad M, Haufroid V.

Ther Drug Monit. 2013 Oct;35(5):608-16. doi: 10.1097/FTD.0b013e318296045b.

PMID:
24052064
9.

Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.

Zuo XC, Ng CM, Barrett JS, Luo AJ, Zhang BK, Deng CH, Xi LY, Cheng K, Ming YZ, Yang GP, Pei Q, Zhu LJ, Yuan H, Liao HQ, Ding JJ, Wu D, Zhou YN, Jing NN, Huang ZJ.

Pharmacogenet Genomics. 2013 May;23(5):251-61. doi: 10.1097/FPC.0b013e32835fcbb6.

PMID:
23459029
10.

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.

Lunde I, Bremer S, Midtvedt K, Mohebi B, Dahl M, Bergan S, ├ůsberg A, Christensen H.

Eur J Clin Pharmacol. 2014 Jun;70(6):685-93.

11.

CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients.

Gijsen VM, van Schaik RH, Elens L, Soldin OP, Soldin SJ, Koren G, de Wildt SN.

Pharmacogenomics. 2013 Jul;14(9):1027-36. doi: 10.2217/pgs.13.80.

PMID:
23837477
12.

Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients.

Miura M, Satoh S, Kagaya H, Saito M, Numakura K, Tsuchiya N, Habuchi T.

Pharmacogenomics. 2011 Jul;12(7):977-84. doi: 10.2217/pgs.11.33.

PMID:
21635144
13.

The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.

Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P.

Pharmacogenetics. 2004 Mar;14(3):147-54.

PMID:
15167702
14.

Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients.

Moes DJ, van der Bent SA, Swen JJ, van der Straaten T, Inderson A, Olofsen E, Verspaget HW, Guchelaar HJ, den Hartigh J, van Hoek B.

Eur J Clin Pharmacol. 2016 Feb;72(2):163-74. doi: 10.1007/s00228-015-1963-3.

15.

Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients.

Elens L, van Schaik RH, Panin N, de Meyer M, Wallemacq P, Lison D, Mourad M, Haufroid V.

Pharmacogenomics. 2011 Oct;12(10):1383-96. doi: 10.2217/pgs.11.90.

PMID:
21902502
16.

Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.

Shi Y, Li Y, Tang J, Zhang J, Zou Y, Cai B, Wang L.

Gene. 2013 Jan 10;512(2):226-31. doi: 10.1016/j.gene.2012.10.048.

PMID:
23107770
17.

Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.

Aouam K, Kolsi A, Kerkeni E, Ben Fredj N, Chaabane A, Monastiri K, Boughattas N.

Pharmacogenomics. 2015 Dec;16(18):2045-54. doi: 10.2217/pgs.15.138.

PMID:
26615671
18.

Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.

Roy JN, Barama A, Poirier C, Vinet B, Roger M.

Pharmacogenet Genomics. 2006 Sep;16(9):659-65.

PMID:
16906020
19.

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

Staatz CE, Goodman LK, Tett SE.

Clin Pharmacokinet. 2010 Apr;49(4):207-21. doi: 10.2165/11317550-000000000-00000. Review.

PMID:
20214406
20.

Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.

Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH, Wang D, Li Z, He J, Zhong GP, Zhou G, Zhou HH.

Clin Exp Pharmacol Physiol. 2006 Nov;33(11):1093-8.

PMID:
17042920

Supplemental Content

Support Center